Vigil Neuroscience is dedicated to developing therapeutics for neurodegenerative diseases, with a focus on microglia. The company's main product candidate, VGL101, is in Phase I trials and is designed to treat several diseases, including Alzheimer's. The company is also developing a small molecule TREM2 agonist for oral delivery.